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Abstract  
 
Introduction: Urban homeless populations in the UK have been shown to have high 
rates of active tuberculosis, but less is known about the prevalence of latent 
tuberculosis infection (LTBI). This study aimed to estimate the prevalence of LTBI 
among individuals using homeless hostels in London. 
 
Methods: We performed a cross-sectional survey with outcome follow-up in homeless 
hostels in London. Our primary outcome was prevalence of LTBI. Secondary 
outcomes were prevalence of hepatitis B, hepatitis C or HIV infections, and outcomes 
in those referred to healthcare services. Recruitment for the study took place between 
May 2011 and June 2013. To estimate an LTBI prevalence of 10% with 95% 
confidence intervals between 8 and 13% we required 500 participants. 
 
Results: 491/804 (61.1%) individuals agreed to be screened. The prevalence of LTBI 
was 16.5% (81/491; 95%CI:13.2-19.8). In UK-born individuals, a history of 
incarceration was associated with increased risk of LTBI (odds ratio 3.49; 95%CI:1.10-
11.04; p=0.018) after adjusting for age, length of time spent homeless, and illicit drug 
use. Of the three subjects who met English treatment guidelines for LTBI at the time 
of the study, none engaged with services after referral for treatment. Prevalence of 
past hepatitis B infection was 10.4% (51/489; 95%CI:7.7-13.1) and 59.5% (291/489; 
95%CI:55.1-63.9) of individuals were non-immune. Prevalence of current hepatitis C 
infection was 10.4% (51/489; 95%CI:7.8, 13.1).  
 
Conclusions: This study demonstrates the high prevalence of LTBI in homeless 
people in London, and the associated poor engagement with care. There is a large 
unmet need for LTBI and hepatitis C infection treatment, and hepatitis B vaccination, 
in this group.  
 
 
  
What is the key question? 
What is the prevalence of latent tuberculosis infection (LTBI) and blood borne viral 
infections among homeless people in London, and what are the outcomes in those 
referred to healthcare services. 
What is the bottom line? 
People experiencing homelessness in London have a very high prevalence of LTBI, 
hepatitis B and hepatitis C infection and co-infection, compounded by poor 
engagement with care. 
Why read on? 
We report for the first time on the burden of LTBI and blood borne viruses among 
homeless people in a metropolitan UK setting. The findings highlight the need to 
ensure recent improvements in diagnostics and therapeutic can benefit the most 
vulnerable and excluded populations. 
140 character twitter conclusion:  
 
London researchers highlight need for improved access to testing and treatment for 
tuberculosis infection and viral hepatitis among homeless people.  
  
Introduction 
 
Homeless individuals have high rates of active pulmonary tuberculosis and often 
present late to healthcare services.[1] Latent tuberculosis infection (LTBI) has been 
shown to be common in homeless populations in low burden countries[2,3], though 
limited data are available in the UK.  
 
Homelessness and tuberculosis in homelessness populations are both increasingly 
significnant problems in London. Using data collected in a multi-agency database 
about rough sleepers and the wider street population (CHAIN) it is estimated that 
approximately 8,000 people sleep rough annually in London.[4] This number has 
doubled from just under 4,000 in 2010, whilst at the same time there has been has 
been an annual reduction in the number of homeless hostel beds for single people 
and couples without dependents across England of 43,655 in 2010 to 35,727 in 
2016.[5]. In 2014 it was estimated that 3.6% (89/2,498) of cases with social risk factor 
information available had a history of tuberculosis.[6] A study undertaken to estimate 
the point prevalence of active tuberculosis estimated that the overall prevalence was 
27 per 100 000 and was 788 per 100 000 in homeless people.[1] 
 
Developments in testing and treatment for LTBI and blood borne viruses (BBV) provide 
new opportunities for effective diagnosis and management.[7,8] Despite these 
advances, concerns remain about LTBI treatment in this homeless population due to 
poor treatment adherence and the potential for severe hepatotoxicity exacerbated by 
high rates of alcohol- or viral related liver disease.[9] It is also important to determine 
the current ability of health services to successfully treat those homeless people 
identified with a given infection before a systematic screening and treatment 
programme is implemented.  
 
Due to uncertainty regarding the prevalence of LTBI and BBVs in homeless 
populations, doubts remain about the effectiveness and cost-effectiveness of a 
targeted LTBI and BBV screening strategy in this group. We therefore undertook a 
cross-sectional survey to estimate the prevalence of LTBI and BBVs among 
individuals in homeless hostels in London, a group which is broadly representative of 
the homeless population of the UK.  We also examined outcomes of referral to 
healthcare services after 12 months. 
Methods 
 
Study population 
We performed a cross sectional survey testing for LTBI, hepatitis B, hepatitis C and 
HIV in residents of homeless hostels in London. The study was conducted alongside 
the Find and Treat (F&T) service run by the National Health Service. F&T identifies 
cases of active tuberculosis using digital chest radiography and supports patients to 
complete treatment.[20] Recruitment for the study took place between May 2011 and 
June 2013 and convenience sampling was used as individuals were screened within 
the F&T programme. Individuals were eligible to participate in the study if they were 
over 18, resident at a homeless hostel on the day of F&T screening, had a tuberculosis 
screening chest radiograph by F&T (or elsewhere within the last 6 months that could 
be proven), and were able to provide written informed consent.  
 
Socio-demographic and risk factor data including self-reported age, sex, history of 
imprisonment, history of drug and alcohol use, history of homelessness, and country 
of birth were collected by dedicated research team using a paper-based questionnaire. 
The questionnaire was piloted and improved with help from homeless hostel users at 
the start of the study.  
 
Referral to NHS services 
In line with NICE guidance, up to March 2012, individuals diagnosed with LTBI were 
offered advice about tuberculosis symptoms and those co-infected with HIV were 
referred to local health services.[21] After March 2012, all individuals diagnosed with 
LTBI that were under the age of 35 years were to be referred to local health services, 
reflecting new NICE guidance for identifying and managing tuberculosis among hard-
to-reach groups.[22] Individuals with current hepatitis B or hepatitis C infection and 
previously undiagnosed HIV infection were referred to 14 local health services and the 
outcomes were collected 12 months after referral by the research team phoning and 
speaking to clinicians and nurses to whom the patients were referred.  
 
The study received approval from the East of England – Essex National Research 
Ethics Service Committee (number 10/H0302/5).  
 
Laboratory testing 
Whole venous blood samples were collected to test for LTBI and BBVs. LTBI was 
measured using the QuantiFERON-TB Gold gamma interferon release assay 
(Cellestis, Australia) following the manufacturer’s instructions for interpretation (Table 
1).  
 
Hepatitis B surface antigen (HBsAg), core total antibody (anti-HBc), surface antibody 
(anti-HBs) were detected by the Architect immunoassay (Abbott Diagnostics, 
Germany). Hepatitis B infection was classed as current in subjects that tested positive 
for HBsAg at screening with confirmation by HBsAg neutralisation. Hepatitis B was 
classified as confirmed past in those who were HBsAg negative, anti-HBc positive and 
anti-HBs positive and probable past in those who were HBsAg negative, anti-HBc 
positive and anti-HBs negative. For all analyses we combine these two groups of 
confirmed and probable past into one group of past hepatitis B infection and we refer 
to them as such throughout the rest of the paper.  Non-immune hepatitis B status was 
defined by absence of all hepatitis B markers.  
 
Anti-HCV antibody was detected by the Vitros chemiluminescence assay (Ortho 
Clinical Diagnostics). Hepatitis C RNA was measured by either an real-time PCR 
assay based on the method described by Komurian-Pradel et al. [23], or the Abbott 
M2000 Real-Time hepatitis C assay.[24][23][22][21] Samples reactive for anti-HCV but 
with undetectable hepatitis C RNA underwent anti-HCV confirmation by the 
Recombinant Immuno Blot Assay (RIBA, Chiron) or the Line Immunoassay (Inno-Lia, 
Innogenetics). Hepatitis C infection was classed as current in anti-HCV positive 
subjects who tested hepatitis C RNA positive, and past in those who showed 
undetectable hepatitis C RNA with confirmed anti-HCV positivity (Table 1). HIV 
screening was performed by the Architect combined HIV antibody/p24 antigen 
chemiluminiscence assay (Abbott Diagnostics). 
 
Analysis 
The primary outcome for the study was the proportion of subjects with a positive 
QuantiFERON-TB Gold assay result. Based on studies in marginalised populations in 
the United States[2,3,25], we expected a minimum of 10% of participants to test 
positive for LTBI. To measure this within 95% confidence intervals between 8 and 
13%, we required 500 participants. Secondary outcomes were hepatitis B, hepatitis C, 
and HIV status, and outcomes in those referred to healthcare services for all infections. 
Data from the paper questionnaires were entered onto a Microsoft Access database 
created for the study. Categorisation of categorical variables, methods of assessment 
and treatment of missing data are presented in a supplementary Appendix. A 
descriptive analysis of baseline variables and their association with primary and 
secondary outcomes was performed. We considered age, a priori, as a confounding 
variable for LTBI. History of imprisonment, history of drug and alcohol use, history of 
homelessness and country of birth were considered as exposure variables and a 
logistic regression model was used to examine the evidence for these as risk factors 
for LTBI. Data were analysed in Stata version 14. 
Results 
 
Study population 
After accessing the F&T mobile screening service, 804 individuals were approached 
by research staff and invited to participate in the study. A total of 542/804 (67.4%) 
individuals consented to take part (Figure 1). 51 (9.4%) individuals were subsequently 
excluded, mainly due to a lack of venous access for blood sampling (n=31). A total of 
491 individuals were therefore included in the analysis. A majority of participants 
(437/491, 89.0%) were men aged between 30 and 49 (257/491, 52.3%), born in the 
UK (305/491, 62.1%) and current tobacco smokers (394/491, 80.2%). Most (443/491, 
90.2%) reported to have been homeless for one or more years. Just over half 
(263/481, 54.7%) had spent time in prison. Drug use was common with 107/491 
(21.8%) ever having smoked heroin or crack cocaine and 86/491 (17.5%) ever having 
injected either crack cocaine or heroin. A large number of individuals (202/477, 42.3%) 
had ever been concerned about their drinking, or had had a health worker express 
concern about their alcohol consumption. Results of testing are shown in Tables 1 and 
2 and in Figures 2 and 3.  
 
Latent tuberculosis infection 
The overall prevalence of LTBI was estimated at 81/491 (16.5%; 95% CI 13.2, 19.8). 
Prevalence was higher in those born outside of the UK (52/186, 28.0%; 95% CI 21.4, 
34.4) relative to those born in the UK (29/305, 9.5%; 95% CI 6.2, 12.8), but both were 
substantially higher than the 1.6% (95% CI 0.2, 5.7) prevalence found in inflammatory 
bowel disease patients screened for LTBI before initiation of anti-TNFα therapy in the 
UK (Figure 2).[26] A multivariable analysis was conducted to identify risk factors for 
LTBI in those individuals born in the UK. There was evidence that a history of 
imprisonment was associated with an increased risk of LTBI (OR 3.49; 95% CI 1.10, 
11.04; p=0.018) after adjusting for age, length of time spent homeless, and any illicit 
drug use (Table 3).  
 
Blood borne viruses 
Current Hepatitis B as confirmed by HBsAg neutralisation was 7/489 (1.4%; 95% CI 
0.4, 2.5). A large proportion of participants (51/489, 10.4%; 95% CI 7.7, 13.1) had 
evidence of past hepatitis B infection. The number of individuals who were non-
immune to hepatitis B was 291/489 (59.5%; 95% CI 55.1, 63.9), and was lower for 
those who had ever injected drugs (23/85, 27.1%; 95% CI 17.4, 36.7; Figure 3). The 
majority of individuals that tested non-immune to hepatitis B (226/291, 77.7%) did not 
recall whether they had been previously vaccinated and 29/291 (10.0%) reported 
never having received vaccination. 120(41.2%; 120/291) had spent time in a UK 
prison. Only four non-immune individuals reported being vaccinated against hepatitis 
B more than once.  
 
Among a total of 64/491 (13.0%; 95% CI 10.0, 16.0) subjects with anti-HCV 
seropositivity, 51 (10.4%; 95% CI 7.8, 13.1) tested positive for hepatitis C RNA 
indicating current infection. The remaining 13 subjects (2.7%; 95% CI 1.2, 4.1) showed 
confirmed anti-HCV reactivity in the absence of hepatitis C RNA, indicating a resolved 
infection. The number of individuals with past or current hepatitis C was higher in those 
who had ever injected drugs (46/86, 53.4%; 95% CI 42.4, 64.3). However, those with 
no injecting drug history (12/405, 3.0; 95% CI 1.3, 4.6) had higher levels than the 
general population estimates in the UK (0.4%).[27] The highest risk of hepatitis C was 
found in those individuals who had been injecting drugs for more than 10 years (Figure 
4), but there was already an increase in prevalence when comparing injecting for 2-9 
years vs. 1 year or less. In those diagnosed with LTBI, the frequency of co-infection 
with either hepatitis B or hepatitis C (past or current) was 37.0% (95% CI 26.3, 47.8) 
and co-infection with both hepatitis B and hepatitis C (past or current) was 16.2% (95% 
CI 9.7, 24.7). 
 
Prevalence of HIV seropositivity was 1.02% (95% CI 0.1, 1.9), all cases were due to 
HIV-1 and all subjects were previously aware of their diagnosis. 
 
Clinical management and outcome 
A total of 81 individuals had a positive LTBI test result, none of whom were co-infected 
with HIV. Three individuals that were diagnosed with LTBI after March 2012 and the 
introduction of updated NICE treatment guidelines, were referred to local health 
services for chemoprophylaxis (Table 4). One subject declined referral, and at twelve 
months follow up, the remaining two had disengaged with services and had not started 
treatment.  
 
Among subjects with a current hepatitis B infection, all 7 accepted a referral; 6 of 7 
were seen at least once in specialist services, none of whom was deemed to require 
immediate antiviral therapy over 12 months following diagnosis.  
 
Among the subjects with current hepatitis C infection, 49/51 (96.1%) subjects accepted 
a referral to specialist services. Two patients initiated interferon-based treatment 
(3.9%; 2/51) with one having completed treatment and one still on treatment at 12 
months follow up. A further 19 (37.3%; 19/51) subjects were seen at least once over 
12 months of follow-up and remained under review in the absence of treatment; 28 
(54.9%; 28/51) individuals were lost to follow up after referral.    
 
Discussion 
 
This study demonstrates a burden of latent tuberculosis and blood borne virus 
infections in a London homeless population at levels that are substantially higher than 
the general population. Although, we found that the greatest risk of LTBI was in those 
born outside the UK, around 10% of UK-born homeless adults were infected. UK born 
individuals with a history of imprisonment had more than three times the risk of LTBI 
compared to other UK born participants. During the study, referral rates for treatment 
for latent tuberculosis infection were low due to the criteria in operation at the time.  
Under new 2016 NICE guidelines[19] all those with a positive test under the age of 65 
would be referred for treatment. Therefore, instead of three people (4%; 3/81) being 
referred, 76 (93.8%; 76/81) would now be eligible for treatment. 
Significantly higher levels of current and past hepatitis B were seen in this study 
compared to the general population (1.4% and 10.4% respectively). A history of 
hepatitis B vaccination was higher in those reporting a history of injecting drug use, 
possibly as a result of targeted vaccination in this population, but there remained a 
substantial proportion of this homeless population who were non-immune and who 
would benefit from vaccination. The levels of hepatitis B are particularly important to 
address in this population given the risk of onward transmission due to poor living 
conditions and low immunisation levels. No patients were initiated on treatment, 
however, this is not necessarily unexpected given the prolonged clinical assessment 
(typically 2-3 appointments spaced out by a few months) required before treatment 
initiation for hepatitis B. 
At 13%, the prevalence of hepatitis C infection was high. This was substantially 
increased in participants reporting injecting drug use, but even those without such a 
history had higher levels than the general population. Engagement with health 
services was poor in those diagnosed with current hepatitis C infection, with just over 
half of those referred either not attending appointments or being lost to follow up. In 
only a minority of those referred was antiviral therapy initiated within 12 months. Until 
recently, hepatitis C care in general has been characterised by a small number of 
treatment initiations relative to the number of people needing and accessing care.[27] 
The introduction of interferon-free regimens of short duration (typically 12 weeks) has 
the potential to improve engagement with care in this vulnerable population but the 
impact remains to be formally investigated. In individuals diagnosed with LTBI, co-
infection with either hepatitis B or C (past or current) was high at 37.0%, as was co-
infection with both hepatitis B and C at 16.2%. The implications of this for LTBI 
treatment and risk of hepatotoxicity need to be carefully considered.  
There were several strengths to our study including the sample size achieved in a 
population that is typically described as “hard-to-reach”. We managed to recruit a large 
number of participants as a result of long established links with homeless services 
(through F&T). The questionnaires used for the collection of self-reported risk factor 
data were developed and piloted with the target population, and were improved on the 
basis of feedback.  
Due to the nature of the population and the fact that this study was conducted 
alongside a busy NHS clinical service, we were not able to use a formal sampling 
framework for the recruitment of patients, and so utilised convenience sampling. The 
requirement for individuals to be able to consent meant that our results do not include 
individuals who were intoxicated (by drugs or alcohol); and therefore is likely to under-
represent those at highest risk of blood borne virus infection.  
Although it was not possible to collect data on individuals unable to consent or who 
were approached for screening and refused to take up the offer, the homeless 
population taking part in this study included a high proportion of previous rough 
sleepers and people with either current or previous high risk drug and harmful and 
hazardous alcohol use. Males are overrepresented among homeless hostel residents 
and the population sampled are broadly demographically comparable to homeless 
populations nationally according to F&T data collected from extensive screening 
outside London and Homeless Link’s health needs audit.[28] 
We are not aware of other published data estimating the prevalence of LTBI in a large 
representative homeless population in the UK. Previous studies in other high income 
countries (including Italy, Japan, South Korea and USA) have reported LTBI 
prevalence in homeless populations and found rates varying from 16% to 
75.9%.[3,29–32] Comparability with our findings is complicated by highly 
heterogeneous populations, differences between studies, including definition of 
homelessness used, eligibility criteria, uptake, and the test used to diagnose latent 
tuberculosis.  
A recent systematic review and meta-analysis of active tuberculosis and blood borne 
viruses in homeless populations internationally found the prevalence of hepatitis C 
virus infection ranged from 3·9% to 36·2%, and for HIV from 0·3% to 21·1%.[33] None 
of the studies testing for HIV were conducted in the UK, but one hepatitis C study, 
which recruited homeless individuals from shelters, special projects, and medical 
centres in Oxford, found 26.5% of individuals positive based upon oral fluid testing.[34]  
 
Our results highlight the potential value of early intervention for prevention given the 
increasing risk of blood borne viruses associated with greater length of time injecting 
drugs. Every opportunity should therefore be taken to maximize vaccination uptake 
including improving healthcare interventions to those in prison. This finding is 
consistent with our previous work demonstrating the inverse care law with respect to 
influenza vaccination.[35] Our data demonstrated that homeless people’s eligibility for 
influenza vaccination due to clinical risk factors was 38.9% compared with 13.0% of 
the general population, but only 23.7% of those eligible were vaccinated compared to 
national levels of 53.2%. Given this unmet need we believe there is a strong rationale 
for offering universal provision of hepatitis B vaccination to homeless people through 
existing services engaged with this group.[36] Individuals who tested HBsAg positive 
generally engaged with services after referral, whereas those diagnosed with hepatitis 
C infection showed suboptimal engagement. Further studies are required to determine 
whether expanded availability of interferon-free regimens of short duration will 
increase engagement in this population. 
 
Homelessness has increased dramatically in the UK since 2010 and the number of 
people seen rough sleeping has doubled nationally.[37,38] These populations 
represent the extreme end of health inequalities in high-income countries and 
experience a high burden of preventable morbidity and mortality from infectious and 
non-infectious disease.[39,40]  Our study demonstrates for the first time the high 
prevalence of undiagnosed LTBI, hepatitis B and C, in homeless populations in the 
UK and a large unmet need for hepatitis B vaccination. Our findings also clearly 
illustrate the requirement for intensive case management and ongoing support to 
ensure that testing can translate into treatment opportunities. The very high rates of 
co-infection demonstrated highlight the importance of service integration through 
combined testing and treatment pathways.[41] NICE now recommend that persons 
accessing targeted mobile radiology should be offered tests for BBV[19] and our data 
provide the basis to estimate the cost effectiveness of this approach. The recent 
national collaborative TB strategy[42] commits to new investment in a national 
outreach service in line with the proven Find & Treat outreach model.[20] Our findings 
reinforce the need for an integrated screening and treatment support model, whilst 
highlighting the ongoing complexity found in this population plus the support they will 
require through such services. 
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Tables  
 
Table 1. Definitions of classifications used for latent tuberculosis infection, hepatitis B, 
hepatitis C, and HIV 
 
Infection  
(number screened) 
Classification  
status 
Definition Number 
classified(%a) 
Latent 
Tuberculosis  
(N=489) c 
Positiveb TB specific antigen 
response >0.35 IU/ml, 
and no evidence of active 
disease on clinical 
assessment 
81 (16.5) 
 Negative TB specific antigen 
response <0.35 IU/ml  
408 (83.1) 
Hepatitis B 
(N=489)c 
Current  HBsAg positive, anti-HBc 
negative, anti-HBs 
negative 
7 (1.4) 
Past 
 
HBsAg negative, anti-
HBc positive, anti-HBs 
positive (confirmed; 
N=43) 
 
Or 
 
HBsAg negative, anti-
HBc positive, anti-HBs 
negative (probable past; 
N=8) 
51 (10.4) 
 Immune probably 
through vaccinationd 
HBsAg negative, anti-
HBc negativee, anti-HBs 
positive 
140 (28.7) 
 Non-immune HBsAg, anti-HBc, anti-
HBs negative 
291 (59.5) 
Hepatitis C 
(N=491) 
Current Anti-HCV positive and 
HCV RNA positive 
51 (10.4) 
 Past Anti-HCV positive, HCV 
RNA negative, and RIBA 
positive 
13 (2.7) 
 Uncertain past 
history 
Anti-HCV positive or 
equivocal, HCV RNA 
negative and no RIBA or 
insufficient sample for 
testing 
 
3 (0.6) 
 Negative Anti-HCV and HCV RNA 
negative  
424 (86.4) 
HIV 
(N=491) 
Seropositive Anti-HIV/p24 antigen 
positive 
5 (1.0) 
 Seronegative Anti-HIV/p24 antigen 
positive 
486 (99.0) 
a Denominator for each percentage is number screened, in first column 
b Further details available from Cellestis, Australia, including interpretation of 
controls.[43] 
c Two missing LTBI results as indeterminate, and two missing hepatitis B test results 
due to insufficient sample for testing.  
d Median anti-HBs levels were 195 IU/L (IQR 46-945).  
e Three subjects had equivocal anti-HBc and negative anti-HBe. 
 
  
Table 2. Baseline demographic and clinical characteristics for participants stratified by 
test results for latent tuberculosis infection, hepatitis B and C. 
 
  All Quantiferon Positive Hep B Positivea Hep C Positiveb 
  N N % N % N % 
                
All 491 81 16.5 58 11.9 64 13.0 
                
Age [years]               
18-29 69 8 11.6 6 8.7 3 4.3 
30-49 257 39 15.2 28 10.9 43 16.7 
50+ 165 34 20.6 24 14.5 18 10.9 
                
                
Sex                
Female 54 4 7.4 5 9.3 3 5.6 
Male 437 77 17.6 53 12.1 61 14.0 
                
Born in the UK               
Yes 305 29 9.5 29 9.5 50 16.4 
No 186 52 28.0 29 15.6 14 7.5 
                
Total time spent homeless             
<1year 48 8 16.7 6 12.5 4 8.3 
1 year 135 18 13.3 16 11.9 13 9.6 
2-3 years 141 28 19.9 19 13.5 11 7.8 
>3 years 167 27 16.2 17 10.2 36 21.6 
                
Has ever spent time in prison           
No 218 35 16.1 27 12.4 12 5.5 
Yes 263 45 17.1 30 11.4 50 19.0 
Missing 10  1    1    2   
                
                
Illicit drug usage               
Neither 298 44 14.8 27 9.1 13 4.4 
Has ever smoked heroin 
/ crack 107 20 18.7 14 13.1 5 4.7 
Has ever injected drugs 86 17 19.8 17 19.8 46 53.5 
                
Case currently smokes 
cigarettes               
No 97 18 18.6 10 10.3 2 2.1 
Yes 394 63 16.0 48 12.2 62 15.7 
                
Participant or health worker ever been concerned about drinking       
No 275 51 18.5 30 10.9 24 8.7 
Yes 202 28 13.9 25 12.4 36 17.8 
Missing 14 2  3  4  
a Sum of current and past hepatitis B 
b Sum of current and past hepatitis C 
Note: HIV data not included to reduce risk of deductive disclosure.  
 
Table 3. Logistic regression results of risk factors for latent tuberculosis infection in 
UK born homeless 
 
Risk Factor 
Univariable Odds Ratio 
(95%CIs) 
Multivariable Odds Ratio 
(95%CIs) p-value* 
     
Age    
<30 1.0 1.0  
30-49 1.36 (0.61, 3.07) 0.69 (0.14, 3.51)  
50+ 1.98 (0.86, 4.53) 2.04 (0.41, 10.05) 0.07 
     
Total time spent homeless    
<1year 1.0 1.0  
1 year 0.77 (0.31, 1.91) 0.32 (0.06, 1.79)  
2-3 years 1.24 (0.52, 2.94) 0.79 (0.18, 3.44)  
>3 years 0.96 (0.41, 2.29) 0.82 (0.20, 3.32) 0.43 
     
Has ever been to prison    
No 1.0 1.0  
Yes 1.08 (0.67, 1.75) 3.49 (1.10, 11.04) 0.018 
     
Illicit drug usage    
Neither 1.0 1.0  
Has ever smoked heroin / 
crack 1.33 (0.74, 2.37) 1.44 (0.49, 4.22)  
Has ever injected drugs 1.42 (0.77, 2.64) 2.65 (0.92, 7.62) 0.20 
     
*Likelihood ratio test; 2 
indeterminate IGRA results 
grouped with negative results.    
   
Table 4. Outcomes of referral to clinical services for positive cases of latent 
tuberculosis, hepatitis B and hepatitis C. 
Outcome at 12 months 
LTBI positive  
N (%) 
HBV 
positive   
N (%) 
HCV positive  
N (%) 
 
   
Diagnosed and eligible for referral 3 (100.0) 7 (100.0) 51 (100.0) 
 
   
Treatment started    
On treatment 0 (0) 0 (0) 1 (2.0) 
Completed treatment 0 (0) 0 (0) 1 (2.0) 
Incomplete treatment 0 (0) 0 (0) 0 (0) 
    
Engaged with services, no treatment    
Seen, discharged, no treatment 
required 0 (0) 6 (85.7) 0 (0) 
Under review, no treatment at present 0 (0) 0 (0) 19 (29.4) 
    
No engagement with services    
DNA, discharged/ LFU 2 (66.6) 1 (14.3) 28 (49.0) 
Declined referral  1 (33.3) 0 (0) 2  (3.9) 
        
    
  
 
  
Figures 
 
Figure 1. Recruitment flow chart 
 
 
 
* It was operationally extremely intensive to collect data on the number of individuals 
who were eligible, approached and refused screening, therefore these data were only 
collected at the start of the study. These numbers are therefore estimated on the basis 
of data collected at the start of study (numbers in parenthesis). 
  
Figure 2. Prevalence of latent tuberculosis infection, hepatitis B and hepatitis C, 
compared to nationally representative samples 
 
 
 
General population comparators taken from published sources: LTBI[26]; Hepatitis 
B[44]; Hepatitis C[27]. Hepatitis B & C results from current study were sum of current 
and past hepatitis B or C. 
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Figure 3. Immunity to Hep B across study and by history of injecting drug use. 
 
 
 
* Immune due to hepatitis B vaccination 
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Figure 4. Risk of hepatitis B and C with increasing time of injecting drug use.  
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